002750 Kunming Longjin Pharmaceutical
- 3.00
- +0.14+4.90%
Kunming Longjin Pharmaceutical News
*Special Treat Longjin (002750.SZ): Received the pharmaceutical registration certificate for sildenafil citrate orally disintegrating tablets.
ST Longjin (002750.SZ) released an announcement that the company's controlling subsidiary, Yunnan Longjin Kangyou Biomedical Co., Ltd...
*ST Longjin: 2024 Third Quarter Report
*ST Longjin: 2024 Semi-Annual Report Summary
*ST Longjin: 2024 Semi-Annual Report
ST Longjin (002750.SZ) released its performance for the first half of the year, with a net loss of 4.224 million yuan.
*ST Longjin (002750.SZ) released its 2024 semi-annual report, during the reporting period, the company achieved operating income...
Special treat Longjin (002750.SZ): As of August 9, the number of shareholders in the company was 38,065.
On August 14th, Gelunhui reported that as of the latest date of August 9, 2024, the number of shareholders in Special Treat Longjin (002750.SZ) was 38,065.
Express News | *ST Longjin: There are no major issues that should have been disclosed but have not been disclosed.
Kunming Longjin Pharmaceutical: 2024 Interim Performance Forecast
*Special Treat Longjin (002750.SZ): Expected to lose between 3.6 million yuan and 4.9 million yuan in the first half of the year.
On July 10th, Gelunhui reported that *ST Longjin (002750.SZ) announced its performance forecast for the first half of 2024, with a net loss of 3.6 million yuan to 4.9 million yuan attributable to shareholders of the listed company, compared with a loss of 15.7777 million yuan in the same period last year. After deducting non-recurring gains and losses, the net loss was 9.7 million yuan to 13.15 million yuan, compared with a loss of 19.4725 million yuan in the same period last year. The basic earnings per share were expected to be between a loss of 0.0090 yuan/share and a loss of 0.0122 yuan/share. Due to the continued impact of policy factors such as medical insurance payment restrictions, hospital prescription restrictions, and the company's injection of scutellaria baicalensis extract price reduction by 67%.
Longjin Pharmaceutical (002750.SZ): Net loss of 4.4918 million yuan in the first quarter
Gelonghui, April 29 | Longjin Pharmaceutical (002750.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 26.3884 million yuan, up 22.43% year on year; net profit attributable to shareholders of listed companies was 4.4918 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 6.1091 million yuan; basic earnings per share - 0.0112 yuan.
The traditional Chinese medicine sector fell at the beginning of the market, and Dali Pharmaceutical fell more than 8%
Gelonghui, March 28 | Dali Pharmaceutical fell more than 8%, followed by Longjin Pharmaceutical, Xiangxue Pharmaceutical, Kanghui Pharmaceutical, and Guangdong Wannianqing.
Pharmaceutical and medical stocks declined at the beginning of the market, leading the decline in the direction of AI pharmaceuticals and CRO
Gelonghui, March 22 | Dali Pharmaceutical fell to a halt, with Longjin Pharmaceutical, Kanghui Pharmaceutical, Celi Healthcare, Hongbo Pharmaceutical, and Pharmaceutical Kangde leading the decline.
Express News | Longjin Pharmaceutical: Shareholder Lixing Industrial plans to reduce holdings by no more than 3%
Longjin Pharmaceutical (002750.SZ): As of February 29, 2024, the number of shareholders of the company was 57,979
Gelonghui March 4 | Longjin Pharmaceutical (002750.SZ) said on the investor interactive platform that as of February 29, 2024, the number of shareholders of the company was 57,979.
Longjin Pharmaceutical (002750.SZ): Stock trading may be subject to delisting risk warning
Longjin Pharmaceutical (002750.SZ) issued an announcement. According to preliminary estimates by the company's finance department, it is expected that the 2023 fiscal year will...
A-share pharmaceutical stocks rebounded across the board
Gelonghui, Feb. 20 | Weight loss pills led the way. Jinkai Biotech and Changshan Pharmaceutical rose and stopped by 20cm, multiple stocks such as Watson Pharmaceuticals, Panlong Pharmaceutical, and Longjin Pharmaceutical closed, and Hanyu Pharmaceutical and Borui Pharmaceuticals rose more than 10%.
The A-share Chinese medicine sector fluctuated and fell, and Tong Ren Tang hit a halt
Gelonghui, January 30 | Tong Ren Tang hit a halt. Previously, Longjin Pharmaceutical fell to a halt, while Jianmin Group, China Resources 39, Kangyuan Pharmaceutical, and Daren Tang had the highest declines.
Longjin Pharmaceutical (002750.SZ): Pre-loss of 63 million yuan to 82 million yuan in 2023
Gelonghui, January 29丨Longjin Pharmaceutical (002750.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 63 million yuan to 82 million yuan, loss of 56,165 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 73 million yuan to 92 million yuan, loss of 57.344 million yuan for the same period last year; basic earnings loss per share of 0.1,573 yuan/share to 0.2047 yuan/share; operating income of 81 million yuan to 99 million yuan per share After-sales Revenue of 75 million yuan to 9
[BT Financial Report Momentary Analysis] Longjin Pharmaceutical's 2023 Quarterly Report: Market Performance with Challenges and Opportunities
Kunming Longjin Pharmaceutical Co., Ltd. (stock code: 002750), since its establishment in 1996, has focused on R&D, production and sales of modern proprietary Chinese medicines and high-end chemical generic drugs. As a national high-tech enterprise, Longjin Pharmaceutical has taken a place in the treatment of cardiovascular and endocrine diseases with many domestic and foreign invention patents. The company's sales strategy, which is guided by clinical value and centered on academic promotion, has successfully expanded to thousands of medical institutions across the country. In terms of assets and liabilities, Longjin Pharmaceutical's 2023 three-quarter report shows that the company's total assets were 683 million yuan, compared to the end of the previous year
Longjin Pharmaceutical (002750.SZ): As of January 10, 2024, the number of shareholders of the company was 57,899
Gelonghui January 16 | Longjin Pharmaceutical (002750.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 57,899.
Analysis
Price Target
No Data
No Data